MedTrace Logo

Acalabrutinib in CNSL

NCT04906902 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2026-02-20

No results posted yet for this study

Summary

This research study is a Phase 1/2 clinical trial testing the safety, tolerance and efficacy of the drug Acalabrutinib for people with recurrent or refractory central nervous system lymphoma (CNSL).

Conditions

  • Central Nervous System Lymphoma
  • Refractory Central Nervous System Lymphoma
  • Recurrent Central Nervous System Lymphoma

Interventions

DRUG

Acalabrutinib

Tablet taken by mouth twice daily

Sponsors & Collaborators

Principal Investigators

  • Lakshmi Nayak, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-23
Primary Completion
2026-04-30
Completion
2027-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04906902 on ClinicalTrials.gov